Actionable news
All posts from Actionable news
Actionable news in PGNX: Progenics Pharmaceuticals Inc.,

Progenics Pharmaceuticals Sets First Quarter 2016 Financial Results Call for May 5

TARRYTOWN, N.Y., April 21, 2016 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc., (PGNX), an oncology company focused on developing innovative ways to target and treat prostate cancer, announced today that it will host a conference call and webcast to review the first quarter ended March 31, 2016 financial results on Thursday, May 5, 2016, at 8:30 a.m. ET.

To participate, please dial (877) 250-8889 (domestic) or (720) 545-0001 (international) and reference conference ID 96882880. A live webcast will be available in the Media Center of the Progenics website,, and a replay will be available for two weeks.

About Progenics

Progenics Pharmaceuticals, Inc. is developing innovative medicines and other products for targeting and treating cancer, with a pipeline that includes several product candidates in later-stage clinical development. These products in development include therapeutic agents designed to precisely target cancer (AZEDRA®, 1095 and PSMA ADC), and PSMA-targeted imaging agents (1404 and PyL) intended to enable clinicians and patients to accurately visualize and manage their disease. In addition, as part of its acquisition of EXINI Diagnostics AB in late 2015, Progenics acquired the EXINI Bone BSI bone scan index product, which is approved for use in Europe, Japan and the U.S. (though not yet available in the...